Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years
Key PointsThe company's GLP-1 therapies are adding indications.
Eli Lilly's stock experienced a remarkable 376% return over the past five years, suggesting a potential repeat performance. Much of this growth is attributed to GLP-1 therapies such as Mounjaro and Zepbound. While similar growth may not be repeated, there are reasons to believe Eli Lilly could still double in value over the next five years, potentially making a $5,000 investment worth over $10,000.
This is due to the versatility of the GLP-1 incretin-based peptide drug tirzepatide, marketed as Mounjaro and Zepbound, which is showing promise in treating various health conditions beyond diabetes. With Mounjaro recently approved to lower cardiovascular event risks and other indications like heart failure and metabolic disease on the horizon, Eli Lilly is investing in a diversified pipeline across oncology, neuroscience, and immunology.
While Eli Lilly did not make the Motley Fool's 10 best stocks list for 2026, its strong revenue growth and promising pipeline present reasons for optimism about its future performance.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
